Oral Screening Tool Identifies Abnormalities in the Mouth

A medical device is used to identify and evaluate abnormalities in the mouth. It was designed especially for populations at increased risk for oral cancer.

The key to reducing the impact of oral cancer is early detection. ViziLite Plus is an oral screening technology that utilizes a chemiluminescent light source (ViziLite) and a vital tissue dye (TBlue) that helps dentists and dental technicians identify and evaluate abnormalities in the mouth that could potentially harbor pathologic changes. The ViziLite Plus exam takes only minutes and is totally painless and noninvasive.

Prior to the introduction of ViziLite Plus the only screening tools available were the manual and visual exam, which helps explain why the mortality and morbidity associated with oral cancer have not markedly improved in the past 40 years. Worldwide clinical trials demonstrated that the conventional visual/tactile examination could fail to identify up to 40% of cancers and precancers. In some studies in the literature, the addition of ViziLite Plus to conventional examination has been shown to result in identification of 100% of pathological lesions

Zila (Scottsdale, AZ, USA), the manufacturer of ViziLite Plus with TBlue, has completed the first phase of expanding into the global market. The product is already on sale in all of the United States, Canada, and Puerto Rica. In Europe, the product is available in the United Kingdom, Ireland, Germany, Spain, Portugal, France, and Greece. In the next phase of its expansion, the company formed distribution agreements in other international markets, including Russia and Belarus, where product registration is in process. These markets and others in the Pacific Rim region, especially China and India, will form the bulk of the company's continued global expansion for ViziLite Plus.

Related Links:
Zila